Nutrition21 Assets Acquired By An Investment Group Led By Messrs. Philip and Michael Satow
The assets of Nutrition 21 have been acquired by an investment group led by Phillip and Michael Satow. The Company will continue to operate as Nutrition 21. Michael Satow will serve as President and Chief Executive Officer and Phillip Satow as Chairman of the Board. Phillip and Michael together have almost 50 years of healthcare experience. Most recently, they founded and built JDS Pharmaceuticals, LLC (“JDS”), a specialty pharmaceutical company focused on the psychiatric and women’s health markets. JDS was sold in 2007 to Noven for $125 million.
Nitrosigine®, Velositol®, nooLVL®, Lustriva™, Chromax®, Zinmax®, and their associated logos are registered trademarks of Nutrition21, LLC. All third party trademarks are the property of their respective owners. Nutrition21, LLC's products are protected by a number of patents including, but not limited to: US Patent Nos. 6,809,115; 6,803,456; 7,576,132; 8,062,677; 8,933,022; 9,005,637; 9,028,879; 9,119,835; 9,421,170; 9,597,404; 9,675,702; 10,183,049; 10,245,325; and 10,363,222.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.